Artificial intelligence is rapidly acquiring a reputation as an unreliable, even dangerous, force in medicine and drug development. Hallucinations, opaque decision-making, and high-profile failures have fueled resistance to its adoption across health care systems. But this backlash reflects not an inherent flaw in AI itself, it reflects how we are choosing to use it.
The dominant mistake is conceptual. We are treating AI as a replacement for human reasoning rather than as a cognitive tool designed to operate alongside it. In doing so, we are asking AI systems to generate original insight, resolve biological uncertainty, and substitute for scientific judgment, roles they were never designed to fulfill. When AI inevitably fails at these tasks, it is blamed for shortcomings that originate in human misuse.
AI is not a thinking entity. It does not reason, hypothesize, or innovate in the way humans do. It is a system constrained by its training data and underlying assumptions. When deployed to explore unknown biological mechanisms or black-box problems without validated reference frameworks, AI models can reinforce confirmation bias, generate false confidence, and amplify error.
These outcomes are not evidence that AI is dangerous; they are evidence that it is being deployed outside its epistemic limits.
Reframing AI as a cognitive adjunct
The more productive framing is to treat AI as a cognitive adjunct, a tool that accelerates pattern recognition, screening, and optimization within human-validated systems. Much like calculators did not replace mathematical reasoning but enhanced it, AI should not be positioned as an autonomous decision-maker. Its value lies in augmenting human logic, not substituting for it.
In drug discovery, this distinction is particularly critical. The failure of AI-driven drug development efforts is often framed as a technological shortcoming, when it is more accurately a failure of experimental context. AI models trained on incomplete, biased, or poorly validated biological data cannot resolve fundamental uncertainty about human physiology. When these models are asked to predict outcomes in systems that lack causal grounding, their outputs become speculative at best.
Reversing the hierarchy in drug discovery
A more robust approach is to reverse the hierarchy: Build human-validated simulation environments first, grounded in meta-analyses of biological success and failure, mechanistic understanding, and real-world clinical data.
Within these constrained and vetted environments, AI can then function as a powerful screening and prioritization tool by being able to identify promising compounds, flagging risk, and optimizing experimental design. This preserves human responsibility for defining biological truth while allowing AI to operate where it is strongest: scale, speed, and pattern detection.
The current backlash against AI in medicine is not a sign that we should abandon it, it is a signal that we must mature in how we use it. Poor implementation has generated poor outcomes, and poor outcomes have generated fear. But fear-driven rejection risks forfeiting one of the most powerful scientific tools we have.
AI does not need to be an oracle to be valuable. It needs to be positioned correctly: as a tool embedded within human judgment, validated systems, and ethical responsibility. If we continue to treat it as a substitute for thinking rather than an aid to it, we will continue to get the failures we designed for and miss the benefits we could have achieved.
Jarelis Cabrera is a biotechnology researcher.
